ZHANG Yong1 CHEN Weizhen1 LU Hanping2 LIANG Changsheng2 LIU Changzheng2 1. 188Re labeling of prostate cancer monoclonal antibody and its biodistribution in tumor-bearing nude mice[J]. Nuclear techniques, 2007, (8): 699-701.
ZHANG Yong1 CHEN Weizhen1 LU Hanping2 LIANG Changsheng2 LIU Changzheng2 1. 188Re labeling of prostate cancer monoclonal antibody and its biodistribution in tumor-bearing nude mice[J]. Nuclear techniques, 2007, (8): 699-701.DOI:
188Re labeling of prostate cancer monoclonal antibody and its biodistribution in tumor-bearing nude mice
To investigate radiolabeled monoclonal antibody 7E11C5.3 against human prostate cancer with 188Re and its biodistribution
188Re-7E11C5.3 was prepared by direct 2-mercaptoethanol-reduction method. Labeling efficiency was measured by paper chromatography. Biodistribution of 188Re-7E11C5.3 was studied in nude mice xenografted with human prostate cancer. The labeling yield of 188Re-7E11C5.3 was 93.16±2.18%. The immunoreactive fraction of 188Re-7E11C5.3 was 74.86±1.86%. After 188Re-7E11C5.3 was injected through tail vein of nude mice
the tumor’s uptake peak time was at 24h
while high uptake in non-tumor tissues was observed at 4h. With time elapsed
the uptake gradually decreased. The blood clearance was rapid. The highest T/NT (radio counts of tumor vs non-tumor tissue) was observed at 24h
and high T/NT was kept till 72h. In conclusion
188Re-7E11C5.3 can be located to xenografted human prostate cancer in vivo and can be used for the study of radioimmunoimaging and radioimmunotherapy.